RxDoctor Payments Data

Carlos Rosas, MD

Family Medicine · Brownsville, TXNPI 1013929272

Payments from drug & device makers

$10,508in general payments, 2019–2025

Across 421 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Amarin Pharma, Inc.$1K
  • AstraZeneca$795
  • Merck$788
  • Amgen$438
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$10,508100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,508 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$145,652
Medicare patients
169
Services billed
2,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide245$265,388
FarxigaDapagliflozin Propanediol183$221,032
MounjaroTirzepatide122$142,819
JardianceEmpagliflozin110$133,483
VascepaIcosapent Ethyl158$100,154
EliquisApixaban92$83,176
TrulicityDulaglutide50$77,069
TradjentaLinagliptin57$71,287
KerendiaFinerenone51$63,182
RybelsusSemaglutide40$62,046
MyrbetriqMirabegron76$58,872
JanumetSitagliptin Phos/Metformin Hcl43$53,066
Icosapent Ethyl95$42,726
LinzessLinaclotide49$40,968
ProliaDenosumab25$40,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Tresiba$1,827$336,603299 claims
AstraZenecaFarxiga$795$221,032183 claims
Lilly USA, LLCMounjaro, Trulicity$1,666$219,888172 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$18$218,050179 claims
MerckJanumet, Januvia$788$93,01796 claims
PfizerEliquis$136$83,17692 claims
BayerKerendia$20$63,18251 claims
Astellas Pharma US IncMyrbetriq$134$58,87276 claims
AbbVieLinzess$107$40,96849 claims
AmgenProlia$438$40,87525 claims
Johnson & JohnsonXarelto$425$36,45531 claims
NovartisEntresto$117$30,03825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →